Just when you thought med-tech companies only make syringes and IV tubes, Poly Medicure decided to play Grey’s Anatomy — launching stents, dialysis machines, and critical care gadgets. Meanwhile, Europe sneezed tariffs, China dumped products like Diwali sale junk, and exports caught a cold. But hey, domestic sales are flexing like Virat Kohli in form.
Keep reading — because between tariff wars, new factories, and a 2,000-patient stent trial, this call was more drama than a Netflix medical thriller.
2. At a Glance
Revenue – ₹403 Cr: Up 5%, because someone had to fight the export flu.
EBITDA – ₹106 Cr: Margin 26.3%, steady like boring but reliable WhatsApp forwards.
PAT – ₹93 Cr: Up 25%, doctors prescribed profits.
Gross Margin – 68.4%: Higher than most influencer discounts.
Domestic biz +20%: Hospitals outside metros finally getting love.
International –1%: Europe still on inventory detox, US slapping tariffs like parking fines.
3. Management’s Key Commentary
“We’ve signed two CDMO contracts with US and Hong Kong firms.” (Translation: Outsourcing isn’t dead — it’s just been rebranded with a fancier acronym.)
“Brazil subsidiary will move us from B2B to B2C.” (Read: Time to sell IV sets on Copacabana.)
“Renal business grew 46%, dialysis machines flying.” (Translation: PM Modi’s dialysis program = PolyMed’s bonus season.)
“Cardiology vertical launched; 1,350 stents already deployed.” (Translation: We’ve officially entered the stent wars — Indian vs imported.)
“International revenue dipped due to tariffs and Chinese dumping.” (Translation: Trade wars turned us into collateral damage.)
“Domestic private sector grew 25%; govt contracts cut.” (Because babu log still want lowest bidder, not quality.)
“Liquidity ₹1,249 Cr; will fund M&A in tech.” (Translation: Shopping spree, but only for ‘cool’ devices, not malls.)
4. Numbers Decoded
Source table
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹403 Cr
+5%
Hero limped, saved by India sales.
EBITDA – The Sidekick
₹106 Cr
+4%
Sidekick stable, but can’t fight tariff villains alone.
PAT – The Overachiever
₹93 Cr
+25%
Profit growth outpaced revenue like T20 strike rate.
Gross Margin – The Flex
68.4%
+170 bps
New cardiology/critical care toys padded the margin.
Domestic Biz – The Darling
₹126 Cr
+20%
Private hospitals love Polymed more than govt tenders.
Exports – The Sulker
₹275 Cr
-1%
Europe detox + US tariffs = sad violin moment.
5. Analyst Questions
Q: Gross margin rose despite export dip — how? Mgmt: “Cardiology/critical care are high-margin.” (Translation: Stents > syringes.)
